RUNX1驱动内皮间质转化参与LMNA心肌病重构
该研究通过空间转录组学与单核多组学分析人LMNA-DCM心脏,发现内皮细胞发生EndoMT相关转录与表观遗传改变;在iPSC来源内皮细胞、心脏类器官及LMNAH222P/H222P小鼠中证实RUNX1介导EndoMT,遗传或药物抑制RUNX1可恢复内皮与心肌功能并减轻纤维化。
要点
- LMNA-DCM心脏内皮细胞出现EndoMT转录与表观遗传特征。
- RUNX1激活驱动内皮功能障碍与间质基因表达。
- 抑制RUNX1可改善内皮与心肌功能并减少纤维化。
核心结论
- RUNX1驱动的EndoMT是连接LMNA突变与纤维化重构的核心机制。
- 内皮转录重编程与RUNX1信号可作为纤维化心肌病的潜在治疗靶点。
研究设计与样本
- 对人LMNA-DCM心脏行空间转录组学与单核多组学分析。
- 采用患者iPSC来源内皮细胞、工程心脏类器官及LMNAH222P/H222P小鼠模型。
- 在体外与体内评估遗传及药物抑制RUNX1的策略。
主要发现
- 人LMNA-DCM心脏中鉴定出具有EndoMT相关转录与表观遗传特征的内皮细胞群。
- LMNA iPSC来源内皮细胞显示内皮功能障碍、间质基因激活及RUNX1表观遗传激活。
- 遗传性RUNX1缺失恢复内皮身份、逆转EndoMT转录程序并正常化内皮调控位点染色质可及性。
- 多细胞心脏类器官中内皮RUNX1激活损害内皮-心肌细胞信号与心肌收缩功能,内皮特异性RUNX1缺失可恢复功能。
- Ro24-7429抑制RUNX1改善体外内皮与心肌细胞功能,并在LMNAH222P/H222P小鼠中减少心肌纤维化、保留心脏功能(包括发病后给药)。
临床怎么用
- RUNX1信号与内皮EndoMT可作为LMNA心肌病抗纤维化治疗的潜在干预靶点。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: LMNA-related dilated cardiomyopathy (LMNA-DCM) is a progressive genetic disorder characterized by conduction disease, malignant arrhythmias, myocardial fibrosis, and heart failure. Although LMNA mutations have traditionally been associated with cardiomyocyte-intrinsic defects, the mechanisms driving fibrotic remodelling remain incompletely understood. METHODS: Spatial transcriptomics and integrated single-nuclei multiomics were performed on explanted human LMNA-DCM hearts to define endothelial transcriptional and epigenomic states associated with fibrosis. Patient-specific induced pluripotent stem cell-derived endothelial cells, engineered cardiac organoids, and the LMNAH222P/H222P mouse model were used to investigate RUNX1-mediated endothelial-to-mesenchymal transition (EndoMT). Genetic and pharmacological RUNX1 inhibition strategies were evaluated in vitro and in vivo. RESULTS: Endothelial populations exhibiting EndoMT-associated transcriptional and epigenomic signatures were identified in human LMNA-DCM hearts. LMNA induced pluripotent stem cell-derived endothelial cells demonstrated endothelial dysfunction, mesenchymal gene activation, and epigenetic activation of RUNX1 following loss of LMNA-mediated repression. Genetic RUNX1 deletion restored endothelial identity, reversed EndoMT-associated transcriptional programmes, and normalized chromatin accessibility at endothelial regulatory loci. In multicellular cardiac organoids, endothelial RUNX1 activation impaired endothelial-cardiomyocyte signalling and cardiomyocyte contractile function, whereas endothelial-specific RUNX1 deletion restored endothelial and myocardial function. Pharmacological RUNX1 inhibition with Ro24-7429 similarly improved endothelial and cardiomyocyte function in vitro and reduced myocardial fibrosis while preserving cardiac function in LMNAH222P/H222P mice, including after disease onset. CONCLUSIONS: RUNX1-driven EndoMT represents a central mechanism linking LMNA mutations to fibrotic remodelling in LMNA cardiomyopathy. These findings support endothelial transcriptional reprogramming and RUNX1 signalling as potential therapeutic targets in fibrotic cardiomyopathy.
引用
- Wu D, Tripathi D, Manhas A, et al. RUNX1-driven endothelial-to-mesenchymal transition contributes to remodelling in LMNA cardiomyopathy. Eur Heart J. 2026. PMID: 42578927. doi:10.1093/eurheartj/ehag619
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。